home / stock / dmac / dmac quote
Last: | $2.51 |
---|---|
Change Percent: | 2.45% |
Open: | $2.49 |
Close: | $2.45 |
High: | $2.515 |
Low: | $2.49 |
Volume: | 3,529 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.51 | $2.49 | $2.45 | $2.515 | $2.49 | 3,529 | 04-25-2024 |
$2.45 | $2.54 | $2.45 | $2.54 | $2.4 | 7,871 | 04-24-2024 |
$2.42 | $2.5599 | $2.42 | $2.5599 | $2.4131 | 5,228 | 04-23-2024 |
$2.51 | $2.36 | $2.51 | $2.56 | $2.26 | 21,158 | 04-22-2024 |
$2.39 | $2.49 | $2.39 | $2.5412 | $2.37 | 21,009 | 04-19-2024 |
$2.49 | $2.545 | $2.49 | $2.61 | $2.45 | 17,421 | 04-18-2024 |
$2.6 | $2.39 | $2.6 | $2.635 | $2.39 | 40,806 | 04-17-2024 |
$2.37 | $2.36 | $2.37 | $2.41 | $2.2906 | 16,028 | 04-16-2024 |
$2.39 | $2.36 | $2.39 | $2.4161 | $2.29 | 28,638 | 04-15-2024 |
$2.43 | $2.54 | $2.43 | $2.57 | $2.4101 | 57,793 | 04-12-2024 |
$2.54 | $2.67 | $2.54 | $2.67 | $2.4 | 38,925 | 04-11-2024 |
$2.65 | $2.7 | $2.65 | $2.82 | $2.65 | 188,112 | 04-10-2024 |
$2.71 | $2.79 | $2.71 | $2.79 | $2.71 | 20,712 | 04-09-2024 |
$2.78 | $2.9 | $2.78 | $2.9 | $2.77 | 20,587 | 04-08-2024 |
$2.98 | $2.95 | $2.98 | $3.2 | $2.87 | 118,472 | 04-05-2024 |
$2.95 | $2.82 | $2.95 | $2.95 | $2.7 | 45,577 | 04-04-2024 |
$2.8 | $2.73 | $2.8 | $2.82 | $2.7 | 25,725 | 04-03-2024 |
$2.73 | $2.72 | $2.73 | $2.745 | $2.67 | 16,852 | 04-02-2024 |
$2.73 | $2.74 | $2.73 | $2.7599 | $2.6736 | 19,622 | 04-01-2024 |
$2.77 | $2.73 | $2.77 | $2.81 | $2.73 | 20,761 | 03-29-2024 |
News, Short Squeeze, Breakout and More Instantly...
DiaMedica Therapeutics Inc. Company Name:
DMAC Stock Symbol:
NASDAQ Market:
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today announced the first patient being dosed in DiaMedica’s relaunch of its pivotal Phase 2/3 ReMEDy2 Trial of...
Conference Call and Webcast March 20 at 8:00 AM Eastern Time / 7:00 AM Central Time ReMEDy2 Clinical Site Activation Commenced in December 2023 Strengthened Management Team with Lorianne Masuoka, M.D., as Chief Medical Officer $53 Million Cash with Runway to 2026 ...
DiaMedica Presents the Protocol and Rationale for ReMEDy2, a Pivotal Trial in Patients Suffering Acute Ischemic Stroke Ineligible for tPA and/or Mechanical Thrombectomy DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developi...